References
Shapiro CL et al. (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19: 3306–3311
Goodwin PJ et al. (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17: 2365–2370
Shapiro CL et al. (2005) Baseline bone mineral density of the total lumbar spine may predict for chemotherapy-induced ovarian failure. Breast Cancer Res Treat 90: 41–46
Shapiro CL (2005) Aromatase inhibitors and bone loss: risks in perspective. J Clin Oncol 23: 4847–4849
Lonning PE et al. (2005) Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23: 5126–5137
Acknowledgements
The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
CLL Shapiro is a Consultant for Novartis and holds an Honorarium from Pfizer. He has research support from Sanofi-Aventis, Pfizer, Genentech, and Roche.
Rights and permissions
About this article
Cite this article
Shapiro, C. Is pamidronate effective in preventing chemotherapy-induced bone loss?. Nat Rev Endocrinol 1, 78–79 (2005). https://doi.org/10.1038/ncpendmet0048
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0048
- Springer Nature Limited